CryptoSlate: USDC Supply Surges as Circle Expands Native Issuance to Celo for Improved Payments

Clever Expansion: Circle’s USDC Stablecoin Joins Celo Network Enhancing Cross-Border Payments and Peer-to-Peer Transactions Circle’s USD Coin (USDC) stablecoin has recently expanded to the Celo Network, bringing with it the potential to revolutionize the world of cross-border payments and peer-to-peer transactions. The Celo Foundation, in a statement on Jan. 30, highlighted the significance of this…

Read More

Trump Sends Haley on a Mission: A Hilarious and Quirky Tale of Presidential Deployment

Trump’s comments about Nikki Haley’s husband at a recent South Carolina rally have sparked controversy and criticism. His remarks questioning the whereabouts of Haley’s husband, who is actually deployed fighting for his country, have been met with backlash and accusations of insensitivity. It is ironic that Trump would question the presence of Haley’s husband, when…

Read More

Revolutionizing Staking: Lightverse’s Cutting-Edge Solutions and Seamless Web3 Integration

LightVerse: Pioneering the Future with Innovative Staking Solutions and Web3 Integration Revolutionizing the Digital Economy LightVerse is at the forefront of technological advancement, pioneering a new paradigm in the digital economy. As a revolutionary service provider, LightVerse offers a unique blend of traditional development and decentralized innovations, unlocking unprecedented opportunities for growth, scalability, and returns….

Read More

Tevogen Bio Achieves Nasdaq Listing Compliance as CEO Reaffirms Commitment to Bridging Information Gap

Tevogen Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement Tevogen Bio Holdings Inc. Announcement WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on…

Read More

Breaking News: Terns Pharmaceuticals Reports Promising Results from Phase 1 Clinical Trial of TERN-601, a Revolutionary Once-Daily Oral GLP-1R Agonist for Obesity Treatment

Positive Results from Terns Pharmaceuticals Phase 1 Trial for TERN-601 Statistically Significant Weight Loss and Well-Tolerated Drug Terns Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 1 trial for TERN-601. The trial showed statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo adjustment. This is a…

Read More